Skip to main content

Search

Site

Search results

12 SEARCH RESULTS FOR

Esketamine

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 2

Pages

Sep 21, 2018 United States Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression   TITUSVILLE, N.J., Sept. 21, 2018  -- The Janssen Pharmaceutical Companies ...

Oct 10, 2018 Belgium Data from five pivotal Phase 3 studies submitted as the basis for Marketing Authorisation Application for esketamine nasal spray   BEERSE, Belgium-- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the ...

Jun 19, 2018 Belgium One long-term study provides evidence that esketamine delayed time to relapse A second study shows esketamine was generally well tolerated with no new safety signals   BEERSE, Belgium-- The Janssen Pharmaceutical Companies of Johnson ...

Oct 18, 2019 Belgium If approved by the European Commission, esketamine nasal spray will offer the first new mechanism of action in 30 years to treat major depressive disorder (MDD) In the phase III clinical development programme with flexible dosing, ...

Sep 09, 2019 United States Global clinical program is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment studies TITUSVILLE, NJ, SEPTEMBER 9, 2019 – The Janssen Pharmaceutical Companies of ...

Dec 19, 2019 Belgium Esketamine nasal spray offers the first new mechanism of action for an antidepressant in 30 years EC approval is based on data from a clinical trial programme in adult patients with treatment-resistant major depressive disorder, ...

Feb 12, 2019 United States If approved, SPRAVATO™ will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen's 60-plus-year history and commitment to research that make a difference for people ...

Sep 04, 2018 United States If approved, esketamine nasal spray would provide the first new mechanism of action in 30 years to treat this debilitating mental illness 1, 2   TITUSVILLE, N.J., Sept. 4, 2018  -- The Janssen Pharmaceutical Companies of Johnson ...

Oct 02, 2019 United States If approved, SPRAVATO ® would be the first treatment for this severely ill population 1 who historically have been excluded from antidepressant clinical trials Submission is based on data from the ASPIRE I & II trials ...

May 21, 2019 United States NEW ORLEANS, May 21, 2019  -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented a   new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting ...

12 SEARCH RESULTS FOR

Esketamine

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 2

Pages